CTOs on the Move

Remedy Partners

www.remedypartners.com

 
Remedy Partners delivers software and services that enable payers, employers and at-risk providers to organize and finance healthcare delivery around a patient`s episode of care. For healthcare providers, Remedy Partners` software, analytics and administrative services support bundled payment contracts with Medicare and Commercial Insurers, often through shared-risk partnerships. For payers, Remedy Partners empowers the development of bundled payment contracting programs and guides development of bundled payment networks. Remedy Partners presently delivers its services to partners at more than 1,000 healthcare locations nationwide.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Remedy Partners raised $86.2M on 07/23/2015

Similar Companies

Catholic Health Services

Catholic Health Services is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Upswing Health

Upswing helps you #getbackintheswing of things. We help athletes identify injuries and find the best path to recovery.

MedAmerica

MedAmerica is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Discovery Laboratories Inc

Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.

Encompass Health System

ENCOMPASS was established in 1985 as a wholly owned for profit subsidiary of the Iowa Foundation for Medical Care (IFMC). IFMC was established in 1972 through the cooperative efforts of business and physicians in response to increasing demands for